genetics of clopidogrel resistance: recent data
Clicks: 216
ID: 162559
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
5.7
/100
19 views
19 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Antiplatelet therapy is one of the most importance in therapy of patients with injured coronary, cerebral and peripheral arteries. The standard of acute coronary syndrome patients treatment is double antiplatelet therapy: acetylsalicylic acid with P2Y12receptor blocker. Some distinguished genetic specifics might lead to the development of resistance to antiplatelet therapy with further thrombotic complications. Current review focuses on the pharmacogenetic specifics of patients than lead clopidogrel resistance.
| Reference Key |
mirzaev2015genetics
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;K. B. Mirzaev;D. A. Sychev;D. A. Andreev |
| Journal | polish journal of management studies |
| Year | 2015 |
| DOI |
10.15829/1560-4071-2015-10-92-98
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.